ESMO 2025 special: Prof. Roupret presents the ALBAN study
About this episode
UROONCO BCa chief editor Dr. Benjamin Pradere (FR) talks to Prof. Morgan Roupret (FR), on the results of the ALBAN trial. A phase 3, randomised, open-label, international study of intravenous atezolizumab and intravesical Bacillus Calmette-Guérin (BCG) vs BCG alone in BCG naïve high-risk, non-muscle invasive bladder cancer.
This interview was recorded at ESMO 2025 in Berlin, Germany. For more updates on bladder cancer, please visit our educational platform UROONCO BCa.
For more EAU podcasts, please go to your favourite podcast app and subscribe to our podcast channel for regular updates: Apple Podcasts, Spotify, EAU YouTube channel.
Get every episode summarized
Each time EAU Podcasts publishes, we email you a written briefing from the transcript — the topics, who appeared, and any specific claims, with the ad reads skipped.
Email me new episodesFree for 3 shows. No card needed.
Hosts & guests
No transcript yet
This episode has not been transcribed. Request it and it moves to the front of the queue.
More episodes
More from EAU Podcasts
Special session at EAU26: GU Cast LIVE
EAU Podcasts
Special session at EAU26: Challenge the UROmigos
EAU Podcasts
ASCO GU26 special: Prof. Karam discusses the results of the LITESPARK-022 study
EAU Podcasts
History of British prostate surgery and urology nursing: History Office at EAU26
EAU Podcasts